Mepolizumab is an anti-interleukin-5 (anti-IL-5) monoclonal antibody that reduces relapse rates and glucocorticoid use in EGPA [17,18]. The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.